Browse SYT2

Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Single-pass membrane protein Cytoplasmic vesicle, secretory vesicle, chromaffin granule membrane Single-pass membrane protein Note=Synaptic vesicles and chromaffin granules.
Domain PF00168 C2 domain
Function

Exhibits calcium-dependent phospholipid and inositol polyphosphate binding properties (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003).

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0001558 regulation of cell growth
GO:0006836 neurotransmitter transport
GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0006906 vesicle fusion
GO:0007269 neurotransmitter secretion
GO:0010720 positive regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0016049 cell growth
GO:0016050 vesicle organization
GO:0016079 synaptic vesicle exocytosis
GO:0017156 calcium ion regulated exocytosis
GO:0017157 regulation of exocytosis
GO:0017158 regulation of calcium ion-dependent exocytosis
GO:0022604 regulation of cell morphogenesis
GO:0023061 signal release
GO:0030307 positive regulation of cell growth
GO:0031346 positive regulation of cell projection organization
GO:0036465 synaptic vesicle recycling
GO:0044801 single-organism membrane fusion
GO:0045055 regulated exocytosis
GO:0045666 positive regulation of neuron differentiation
GO:0045927 positive regulation of growth
GO:0048284 organelle fusion
GO:0048488 synaptic vesicle endocytosis
GO:0048489 synaptic vesicle transport
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048791 calcium ion-regulated exocytosis of neurotransmitter
GO:0050769 positive regulation of neurogenesis
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0051962 positive regulation of nervous system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060627 regulation of vesicle-mediated transport
GO:0061025 membrane fusion
GO:0072583 clathrin-dependent endocytosis
GO:0090174 organelle membrane fusion
GO:0097479 synaptic vesicle localization
GO:0097480 establishment of synaptic vesicle localization
GO:0097484 dendrite extension
GO:0099003 vesicle-mediated transport in synapse
GO:0099504 synaptic vesicle cycle
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
GO:1903305 regulation of regulated secretory pathway
GO:1903859 regulation of dendrite extension
GO:1903861 positive regulation of dendrite extension
GO:1990138 neuron projection extension
Molecular Function GO:0000149 SNARE binding
GO:0005543 phospholipid binding
GO:0005544 calcium-dependent phospholipid binding
GO:0019905 syntaxin binding
GO:0030276 clathrin binding
GO:0043178 alcohol binding
GO:0043533 inositol 1,3,4,5 tetrakisphosphate binding
Cellular Component GO:0008021 synaptic vesicle
GO:0030133 transport vesicle
GO:0030141 secretory granule
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0030672 synaptic vesicle membrane
GO:0042583 chromaffin granule
GO:0042584 chromaffin granule membrane
GO:0070382 exocytic vesicle
GO:0098793 presynapse
GO:0099501 exocytic vesicle membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-1643685: Disease
R-HSA-5663205: Infectious disease
R-HSA-6794361: Interactions of neurexins and neuroligins at synapses
R-HSA-199991: Membrane Trafficking
R-HSA-112316: Neuronal System
R-HSA-168799: Neurotoxicity of clostridium toxins
R-HSA-6794362: Protein-protein interactions at synapses
R-HSA-5250958: Toxicity of botulinum toxin type B (BoNT/B)
R-HSA-5339562: Uptake and actions of bacterial toxins
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SYT2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SYT2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SYT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2680.427
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0920.959
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7230.746
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8850.0209
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0740.109
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6720.342
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2370.563
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2250.704
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3360.152
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SYT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYT2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYT2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYT2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYT2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SYT2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SYT2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSYT2
Namesynaptotagmin II
Aliases CMS7; MYSPC; SytII; Synaptotagmin-2
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SYT2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SYT2.
ID Name Drug Type Targets #Targets
DB00042Botulinum Toxin Type BBiotechSYT2, VAMP1, VAMP23